Abe....another interesting fact about Atalanta, the company Roche cites for partnership. Guess who joined the BOD of Atalanta last year....Alan Sandrock who was the Chief Scientist at Biogen a few years back when Biogen and Anavex did a joint look at 2-73 for MS. Wayne State University had already done clinical work with 2-73 which pointed to its "remyelination" properties for MS, but the conjecture was that Biogen would bury 2-73 because of its advancement of "Aducanumab" now "Aduhelm", FDA approved for Alzheimer's but dead in the market. Sandrock left Biogen shortly after. What Biogen passed on will sink them in the future!
----
Dr. Sandrock spent 23 years at Biogen where he served in positions of increasing responsibility, culminating in his service as executive vice president, research and development, until December 2021. He also served an eight-year term as the company’s chief medical officer, from 2012 to 2020, and on the Biogen Executive Committee, from 2013 to 2021. Earlier in his career, Dr. Sandrock held several senior executive positions at Biogen, including group senior vice president of development sciences, senior vice president of neurology R&D, and vice president of clinical development, neurology. Over the course of his tenure, he led the discovery, development, and regulatory approval of numerous medicines including Aduhelm®, Plegridy®, Spinraza®, Tecfidera®, and Tysabri®. Dr. Sandrock holds a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography) at Massachusetts General Hospital.
Bullish
News 
Market Data 
Discover 
